98%
921
2 minutes
20
Aims And Background: Vascular endothelial cadherin (VE-cadherin) preserves the tightness of the mature vascular network as a component of endothelial adherens junctions. Vascular endothelial growth factor (VEGF) makes VE-cadherin dissociate from complexes with beta-catenin, so that endothelial cells can loosely proliferate and migrate. We searched for relationships between VEGF and VE-cadherin levels in preoperative sera of patients with colorectal cancer (CRC). We also compared VE-cadherin levels of control and preoperative CRC sera in relation to clinicopathological features.
Methods: We measured with an ELISA kit the serum levels of the proteins in preoperative samples from 125 CRC patients and in samples from 16 healthy volunteers.
Results: Serum VE-cadherin was about fourfold higher in CRC patients than in controls (P < 0.00001), with similar results being found in subgroups with different clinicopathological features versus controls. VE-cadherin was not correlated with VEGF in the entire group of CRC patients nor in the subgroups of node-positive and node-negative patients, different grades of histological differentiation (G2 or G3), extent of tumor growth (pT1+pT2 or pT3+pT4), histopathological type (adenocarcinoma or mucinous carcinoma), sex, age, and tumor site (colon or rectum). However, the serum levels of VE-cadherin and VEGF in CRC patients, which were higher than the mean values of controls, tended towards a negative correlation in node-positive patients (P = 0.078, r = -0.279).
Conclusions: VEGF and VE-cadherin seem to be independent markers of angiogenesis in CRC with no significant correlation between their serum levels.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/030089160609200111 | DOI Listing |
J Cancer Res Clin Oncol
September 2025
Division of Gastroenterology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan.
Purpose: Next-generation sequencing (NGS) has revolutionized cancer treatment by enabling comprehensive cancer genomic profiling (CGP) to guide genotype-directed therapies. While several prospective trials have demonstrated varying outcomes with CGP in patients with advanced solid tumors, its clinical utility in colorectal cancer (CRC) remains to be evaluated.
Methods: We conducted a prospective observational study of CGP in our hospital between September 2019 and March 2024.
Rev Gastroenterol Mex (Engl Ed)
September 2025
Departamento de Endoscopia Gastrointestinal, Instituto Nacional de Cancerología, Tlalpan, Mexico City, Mexico.
Introduction And Aims: Sessile serrated adenomas (SSAs) are precursor lesions of colorectal cancer (CRC) in 15-30% of cases, but due to their subtle characteristics, their endoscopic detection is a challenge. The present work aimed to determine the frequency of SSAs in patients with a history of CRC who underwent index and surveillance colonoscopies after their cancer diagnosis.
Material And Methods: An observational cohort study was conducted on patients diagnosed with CRC who underwent an index colonoscopy and at least two surveillance colonoscopies at the Instituto Nacional de Cancerología in Mexico City, between January 2015 and December 2018.
Rev Gastroenterol Mex (Engl Ed)
September 2025
Servicio de Clínica Médica, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Introduction And Aims: The aim of this study was to estimate the number of patients diagnosed with colorectal cancer (CRC) that underwent their first screening colonoscopy and to describe the endoscopic and anatomopathologic findings and characteristics of the patients that had a screening colonoscopy for CRC.
Materials And Methods: A cross-sectional study was conducted that included patients aged 50 to 79 years, with prepaid healthcare at a tertiary care hospital, that underwent a first colonoscopy within the time frame of 2013 and 2022. The demographic data, endoscopic findings, and biopsy results were collected.
J Immunother Cancer
September 2025
Affini-T Therapeutics Inc, Watertown, Massachusetts, USA.
T-cell receptors (TCRs) recognize antigens derived from fragments of somatically expressed proteins that are degraded by the proteasome and presented by specific human leukocyte antigen (HLA) molecules. Recent therapeutic advances using the TCR as a tumor-targeting moiety have focused attention on loss of heterozygosity (LOH) as a potential resistance mechanism. Allele-specific LOH, rather than allele-agnostic, is particularly pertinent, but rarely evaluated.
View Article and Find Full Text PDFBMJ Open Gastroenterol
September 2025
Manchester University NHS Foundation Trust, Manchester, UK.
Objective: People with cystic fibrosis (pwCF) are at significantly increased risk of colorectal cancer (CRC), prompting international recommendations for earlier screening with colonoscopy. The utility of faecal immunochemical testing (FIT) as a screening adjunct in pwCF remains unclear. This study evaluates FIT's diagnostic performance and uptake within a CRC screening programme in a UK CF centre.
View Article and Find Full Text PDF